442 related articles for article (PubMed ID: 18577308)
1. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M
Curr Med Res Opin; 2008 Aug; 24(8):2229-40. PubMed ID: 18577308
[TBL] [Abstract][Full Text] [Related]
2. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
Bonafede MM; Gandra SR; Fox KM; Wilson KL
J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
[TBL] [Abstract][Full Text] [Related]
4. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis.
Yazici Y; Krasnokutsky S; Barnes JP; Hines PL; Wang J; Rosenblatt L
J Rheumatol; 2009 May; 36(5):907-13. PubMed ID: 19332636
[TBL] [Abstract][Full Text] [Related]
5. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate.
Harley CR; Frytak JR; Tandon N
Am J Manag Care; 2003 Oct; 9(6 Suppl):S136-43. PubMed ID: 14577718
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
7. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
[TBL] [Abstract][Full Text] [Related]
8. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.
Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M
Curr Med Res Opin; 2007 Aug; 23(8):1749-59. PubMed ID: 17588306
[TBL] [Abstract][Full Text] [Related]
9. Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population.
Fisher MD; Watson C; Fox KM; Chen YW; Gandra SR
Curr Med Res Opin; 2013 May; 29(5):561-8. PubMed ID: 23489410
[TBL] [Abstract][Full Text] [Related]
10. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
11. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.
Schabert VF; Watson C; Gandra SR; Goodman S; Fox KM; Harrison DJ
J Med Econ; 2012; 15(2):264-75. PubMed ID: 22115327
[TBL] [Abstract][Full Text] [Related]
12. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
[TBL] [Abstract][Full Text] [Related]
13. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
14. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice.
Huang X; Gu NY; Fox KM; Harrison DJ; Globe D
Curr Med Res Opin; 2010 Jul; 26(7):1637-45. PubMed ID: 20429830
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
[TBL] [Abstract][Full Text] [Related]
17. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
18. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis.
Stern R; Wolfe F
J Rheumatol; 2004 Aug; 31(8):1538-45. PubMed ID: 15290732
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
Hansen KE; Hildebrand JP; Genovese MC; Cush JJ; Patel S; Cooley DA; Cohen SB; Gangnon RE; Schiff MH
J Rheumatol; 2004 Jun; 31(6):1098-102. PubMed ID: 15170921
[TBL] [Abstract][Full Text] [Related]
20. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.
Schabert VF; Bruce B; Ferrufino CF; Globe DR; Harrison DJ; Lingala B; Fries JF
Curr Med Res Opin; 2012 Apr; 28(4):569-80. PubMed ID: 22236091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]